Company intelligence / Profile preview
Chengdu MFS Pharma
Chengdu, Sichuan, Chinamfspharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chengdu MFS Pharma is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on metabolic diseases, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), as well as oncology. Its lead program, MFS-1517, is a potent GPR120 agonist designed to address insulin resistance and chronic inflammation. By leveraging its internal medicinal chemistry expertise, MFS Pharma aims to provide high-quality, differentiated therapeutic solutions for patients with high unmet medical needs.
- Therapeutic areas
- OncologyMetabolic DisordersEndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chengdu MFS Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu MFS Pharma.